Ken Griffin Mirum Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$33.68 - $44.74 $653,392 - $867,956	19,400 Added 78.54%	44,100 $1.72 Million
Q2 2024 Aug 14, 2024	BUY	$23.57 - $34.85 $73,067 - $108,035	3,100 Added 14.35%	24,700 $844,000
Q1 2024 May 15, 2024	BUY	$24.92 - $30.02 $276,612 - $333,222	11,100 Added 105.71%	21,600 $542,000
Q4 2023 Feb 14, 2024	BUY	$27.14 - $34.93 $89,562 - $115,269	3,300 Added 45.83%	10,500 $309,000
Q3 2023 Nov 14, 2023	SELL	$24.63 - $32.85 $184,725 - $246,375	-7,500 Reduced 51.02%	7,200 $227,000
Q2 2023 Aug 14, 2023	SELL	$23.51 - $30.09 $126,954 - $162,486	-5,400 Reduced 26.87%	14,700 $380,000
Q1 2023 May 15, 2023	SELL	$19.19 - $24.1 $28,785 - $36,150	-1,500 Reduced 6.94%	20,100 $482,000
Q4 2022 Feb 14, 2023	BUY	$17.59 - $23.83 $70,360 - $95,320	4,000 Added 22.73%	21,600 $421,000
Q3 2022 Nov 14, 2022	BUY	$19.98 - $29.44 $351,648 - $518,144	17,600 New	17,600 $370,000

190

54M

177K

167K

Ticker MIRM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,751,700
Market Cap $1.7B
Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.